Double-blind levamisole trial in resectable lung cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Lung carcinoma is a leading cause of cancer mortality.
• Adjuvant therapies are crucial for improving outcomes in resectable primary lung carcinoma.
• Levamisole is an immunomodulatory agent with potential anti-cancer properties.

Purpose of the Study:

• To evaluate the efficacy of levamisole as an adjunct to surgery in patients with resectable primary lung carcinoma.
• To determine optimal dosing and patient stratification for levamisole therapy.

Main Methods:

• Prospective, double-blind, placebo-controlled trial.
• Third interim analysis of patient data.
• Levamisole administered as an adjunct to surgical resection.
• Dosage adjusted based on patient weight (2.5 mg/kg/day).

Main Results:

• A significant beneficial effect of levamisole was observed in patients weighing 70 kg or less.
• Patients receiving adequate levamisole dosage showed near-complete elimination of distant metastases.
• The therapeutic effect was more pronounced in patients with a heavier tumor load at the time of surgery.

Conclusions:

• Levamisole, at a dosage of 2.5 mg/kg/day, is a beneficial adjunct to surgery for specific lung carcinoma patient subgroups.
• Weight and tumor burden are important factors in predicting levamisole efficacy.
• Pre-operative and post-operative administration of levamisole warrants further investigation.